A Prospective, Multi-center, Observational Study for Signal-C Test Evaluation
Conditions: Colorectal Cancer; Advanced Adenocarcinoma Interventions: Device: Signal-C ™ Sponsors: Universal Diagnostics; Premier Research Group plc; Yanuvia, LLC; Science 37 Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 29, 2023 Category: Research Source Type: clinical trials
Watch-and-Wait Approach With Dostarlimab in Localized dMMR/MSI-H Gastric Cancer: GERCOR Phase II Study
Conditions: Adenocarcinoma - GEJ; Gastric Adenocarcinoma Intervention: Drug: Dostarlimab Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 28, 2023 Category: Research Source Type: clinical trials
Watch-and-Wait Approach With Dostarlimab in Localized dMMR/MSI-H Gastric Cancer: GERCOR Phase II Study
Conditions: Adenocarcinoma - GEJ; Gastric Adenocarcinoma Interventions: Drug: Dostarlimab Sponsors: GERCOR - Multidisciplinary Oncology Cooperative Group Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 28, 2023 Category: Research Source Type: clinical trials
HER-2 Expression in Pancreatic Duct Adenocarcinoma
Condition: Pancreatic Adenocarcinoma Intervention: Genetic: immunohistochemical approach Sponsor: Sohag University Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2023 Category: Research Source Type: clinical trials
Efficacy and Safety of Tislelizumab for Lung Adenocarcinoma With Asymptomatic Brain Metastatic
Condition: Lung Adenocarcinoma Intervention: Drug: Tislelizumab,Platinum Sponsor: Hebei Medical University Fourth Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2023 Category: Research Source Type: clinical trials
Efficacy and Safety of Tislelizumab for Lung Adenocarcinoma With Asymptomatic Brain Metastatic
Conditions: Lung Adenocarcinoma Interventions: Drug: Tislelizumab,Platinum Sponsors: Hebei Medical University Fourth Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2023 Category: Research Source Type: clinical trials
HER-2 Expression in Pancreatic Duct Adenocarcinoma
Conditions: Pancreatic Adenocarcinoma Interventions: Genetic: immunohistochemical approach Sponsors: Sohag University Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2023 Category: Research Source Type: clinical trials
Improving Pancreatic Cancer Care by the Use of Computational Science and Technology
Conditions: Pancreatic Cancer; Pancreatic Cyst; Pancreatic Adenocarcinoma; Pancreatic Diseases; Pancreas Adenocarcinoma; Pancreas Cyst Intervention: Other: No interventions Sponsors: UMC Utrecht; Catharina Ziekenhuis Eindhoven; St. Antonius Hospital; Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA); University Medical Center Groningen; Medisch Spectrum Twente; Erasmus Medical Center; Maastricht University Medical Center; Leiden University Medical Center; NYU Langone Health; Johns Hopkins University; Delft University of...
Source: ClinicalTrials.gov - September 26, 2023 Category: Research Source Type: clinical trials
Improving Pancreatic Cancer Care by the Use of Computational Science and Technology
Conditions: Pancreatic Cancer; Pancreatic Cyst; Pancreatic Adenocarcinoma; Pancreatic Diseases; Pancreas Adenocarcinoma; Pancreas Cyst Interventions: Other: No interventions Sponsors: UMC Utrecht; Catharina Ziekenhuis Eindhoven; St. Antonius Hospital; Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA); University Medical Center Groningen; Medisch Spectrum Twente; Erasmus Medical Center; Maastricht University Medical Center; Leiden University Medical Center; NYU Langone Health; Johns Hopkins University; Delft University of Technology Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 26, 2023 Category: Research Source Type: clinical trials
A Study to Evaluate the Safety and Efficacy of A2B694, a Logic-gated CAR T, in Subjects With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Conditions: Solid Tumor, Adult; Colorectal Cancer; NSCLC; Non Small Cell Lung Cancer; NSCLC, Recurrent; Non-Small Cell Squamous Lung Cancer; Pancreas Cancer; Pancreatic Neoplasm; Colorectal Adenocarcinoma; CRC; Colon Cancer; Rectal Cancer; Cancer; Ovar ian Cancer; Ovarian Neoplasms; Mesothelioma; Mesothelioma, Malignant; Ovary Cancer; Lung Cancer; MESOM Interventions: Biological: A2B694; Diagnostic Test: xT CDx with HLA-LOH Assay Sponsors: A2 Biotherapeutics Inc.; Tempus Labs Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 25, 2023 Category: Research Source Type: clinical trials
